Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of PM01183 in metastatic breast cancer with BRCA1/2-associated or unselected cohorts
2011-006108-11Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Feb 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lurbinectedin in breast cancer (2 cohorts), sponsored by PharmaMar. Primary endpoint: Overall response rate. Started Feb 2012; status: completed.
02
Drugs
lurbinectedin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-006108-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006108-11.